NEWCASTLE-UPON-TYNE and CHAPEL-EN-LE-FRITH, England, November 9, 2010 /PRNewswire/ -- A pioneering new assay-ready, on-demand chemical supply service has been announced today as the result of a partnership between Molplex and Peakdale Molecular.
The new service will radically cut the cost of accessing chemical libraries for drug discovery by providing sophisticated chemical selection systems, allowing customers to choose only those chemicals most likely to be useful and only in the quantity and format they need for a testing.
Eliminating the high start-up costs of chemistry in early drug discovery, the service aims to empower the emerging ecosystem of Micro Pharmas by helping them to succeed at inventing new medicines at lower cost.
Molplex CEO David Leahy said: Peakdale and Molplex share the same vision of delivering high quality chemical services on demand that enable innovative drug discovery teams to invent new medicines. We're committed to offering high quality chemical supply services at low cost by using novel technology and allowing customers to order economically and affordably.
Peakdale CEO, Ray Fisher said We have over 25 years experience in providing high quality and knowledgeable chemical synthesis and supply support to the world's largest pharmaceutical companies. Molplex's highly innovative on demand drug discovery service puts our high quality chemistry and deep chemical experience at the service of drug discovery teams based anywhere in the world.
About Molplex
Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines by making sophisticated drug discovery information and laboratory systems available on-line and on demand. CEO David Leahy previously founded Cyprotex PLC, now the world's largest ADME Tox service supplier. The Molplex team has extensive drug discovery experience and has developed sophisticated software systems for automated drug design. For more information visit http://www.molplex.com
About Peakdale
Peakdale Molecular based in Chapel-en-le Frith, Derbyshire has been established as a provider of research services to the pharmaceutical and biotechnology industry since 1992. In state of the art laboratories with over 90 chemists it continues to provide problem solving expertise from discovery to scale up across Europe and the USA. For more information on Peakdale Molecular, please visit http://www.peakdale.co.uk
Contact Details David Leahy, CEO, Molplex Ltd. info@molplex.com, Tel: US: +1-408-905-2900 Europe: +44-191-211-196 Dr. Mick Durrant, Director of Business Development, Peakdale Molecular Ltd. enquiries@peakdale.co.uk Tel: +44-1298-816-700
SOURCE: Peakdale Molecular Ltd
CONTACT: Contact Details: David Leahy, CEO, Molplex Ltd.,info@molplex.com, Tel: US: +1-408-905-2900, Europe: +44-191-211-196; Dr.Mick Durrant, Director of Business Development, Peakdale Molecular Ltd.,enquiries@peakdale.co.uk , Tel: +44-1298-816-700.
Comments